Details for Patent: 5,969,156

Analysis of United States Drug Patent 5,969,156: Scope, Claims, and Landscape

Patent 5,969,156, titled "Antigen binding proteins and peptides and their use in preventing and treating disease," was granted to Celltech R&D Limited on October 12, 1999. The patent describes a class of humanized antibodies and related protein constructs designed to bind to specific antigens involved in inflammatory and autoimmune diseases. The technology is foundational to several therapeutic agents, notably those targeting Tumor Necrosis Factor alpha (TNF-α).

What is the Core Technology Protected by Patent 5,969,156?

The patent’s core technology centers on the development of modified antibodies, specifically humanized monoclonal antibodies, and antibody fragments. These molecules are engineered to exhibit enhanced binding affinity and specificity to target antigens, with a primary focus on TNF-α. The patent claims methods for creating these antibodies, including techniques for reducing immunogenicity and improving their therapeutic efficacy.

The invention addresses the limitations of earlier antibody-based therapies, such as xenogeneic antibodies (derived from non-human species), which often elicited significant immune responses in patients. By "humanizing" the antibody structure, the patent aimed to create molecules that are more readily tolerated by the human immune system, thereby increasing their therapeutic window and reducing adverse effects.

What Specific Claims Does Patent 5,969,156 Encompass?

Patent 5,969,156 contains 16 independent claims covering various aspects of the invention. Key claims include:

• Claim 1: A method of producing a binding protein comprising a human framework region and a non-human complementarity determining region, wherein the binding protein binds to human TNF-α. This claim broadly covers the humanization process for antibodies targeting TNF-α.
• Claim 5: An antibody fragment comprising at least one of the complementarity determining regions of an antibody which binds to human TNF-α, wherein said antibody fragment has a binding affinity for human TNF-α of at least 1 x 10^-9 M. This claim extends protection to antibody fragments, which can offer different pharmacokinetic properties and administration routes compared to full antibodies.
• Claim 8: A hybridoma producing a monoclonal antibody that binds to human TNF-α, wherein the antibody is a humanized antibody according to claim 1. This claim protects the cell lines that produce the specific humanized antibodies described.
• Claim 9: A method of preventing or treating a disease mediated by TNF-α, comprising administering a binding protein as claimed in claim 1. This claim covers the therapeutic application of the patented binding proteins for diseases associated with TNF-α.
• Claim 12: A pharmaceutical composition comprising a binding protein as claimed in claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulated drug product.
• Claim 13: A humanized antibody that binds to human TNF-α, wherein the antibody comprises human framework regions and CDRs derived from the murine monoclonal antibody designated A2. This is a more specific claim, referencing a particular murine antibody that served as the source for the humanized CDRs.
• Claim 14: A DNA sequence encoding a humanized antibody of claim 13. This claim protects the genetic material used to produce the antibody.

The claims establish a broad scope, covering not only the specific antibodies and fragments but also the methods of their production and therapeutic uses. The reference to the murine antibody A2 is significant, as it directly links the patent to early development efforts for a major TNF-α inhibitor.

What is the Significance of the Prior Art and Early Development for This Patent?

The development of Patent 5,969,156 is rooted in advancements in monoclonal antibody technology and a growing understanding of the role of TNF-α in inflammatory diseases. Prior art in the field of antibody engineering, particularly techniques for antibody humanization, was critical. Early research identified TNF-α as a key mediator of inflammation in conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis.

The murine monoclonal antibody A2, which serves as a progenitor for the antibodies claimed in this patent, was a crucial early discovery. However, the use of fully murine antibodies in human therapy was limited by immunogenicity. The innovation protected by Patent 5,969,156 lies in the successful humanization of A2, rendering it a therapeutic candidate with a more favorable safety profile. This process involved identifying and transferring the complementarity-determining regions (CDRs) of the murine antibody into the framework regions of human antibodies, thereby retaining the antigen-binding specificity while reducing the foreign protein content recognized by the human immune system.

Key developments that informed this patent include:

• Discovery of TNF-α: Identification of TNF-α as a pro-inflammatory cytokine involved in numerous autoimmune and inflammatory conditions in the 1980s.
• Monoclonal Antibody Technology: Advances in producing specific antibodies using hybridoma technology (Köhler and Milstein, 1975).
• Antibody Engineering: Development of techniques for modifying antibodies, including chimeric and humanized antibodies, to improve their therapeutic utility and reduce immunogenicity.

The patent represents a significant step in translating basic research on TNF-α and antibody engineering into a practical therapeutic strategy.

What is the Patent Landscape Surrounding TNF-α Inhibitors and Related Technologies?

The patent landscape for TNF-α inhibitors is characterized by a dense network of patents covering various aspects of these biologic therapies. Patent 5,969,156 is a foundational patent within this landscape, but it is surrounded by and has influenced numerous other patents.

Key Areas of Patenting Activity in TNF-α Inhibitors:

• Antibody Sequences and Structures: Patents protecting specific humanized antibodies (e.g., infliximab, adalimumab) and their amino acid sequences.
• Formulations: Patents covering specific drug formulations, including methods of administration, stability enhancers, and delivery systems.
• Manufacturing Processes: Patents on methods for producing, purifying, and manufacturing these large protein molecules, often involving cell culture, fermentation, and downstream processing.
• Therapeutic Uses: Patents claiming the treatment of specific diseases or patient populations with TNF-α inhibitors.
• Polymorphs and Salts: Patents on different crystalline forms of the active pharmaceutical ingredient, which can affect solubility, stability, and bioavailability.
• Biosimilars and Generics: A growing body of patents and patent applications related to the development of biosimilar versions of established TNF-α inhibitors, focusing on demonstrating similarity in terms of quality, safety, and efficacy.

Relationship of Patent 5,969,156 to Other Patents:

Patent 5,969,156 provided the intellectual property foundation for early TNF-α inhibitors. Subsequent patents have built upon this by:

• Claiming specific antibodies derived from this technology: For example, patents covering infliximab (Remicade) and adalimumab (Humira) reference the foundational technology protected by 5,969,156.
• Protecting improvements and modifications: Later patents have focused on refining antibody structure, improving efficacy, reducing side effects, or developing novel delivery methods.
• Expanding therapeutic indications: As research progressed, new patents emerged for the use of TNF-α inhibitors in a wider range of autoimmune and inflammatory conditions.
• Developing biosimilar versions: The expiry of key patents, including those related to the initial TNF-α inhibitors, has led to extensive patenting activity by companies developing biosimilar products, aiming to secure market exclusivity for their specific biosimilar versions and manufacturing processes.

The expiration of Patent 5,969,156 has allowed for the development and introduction of biosimilar versions of early TNF-α inhibitors, intensifying competition in the market for these therapies. However, the patent landscape remains complex, with ongoing patenting in areas such as novel antibody formats, combination therapies, and advanced drug delivery systems.

How Has Patent 5,969,156 Influenced the Development of TNF-α Inhibitors?

Patent 5,969,156 has significantly influenced the development and commercialization of TNF-α inhibitors. It provided critical intellectual property protection for one of the earliest successful classes of biologic drugs targeting TNF-α.

Key Impacts:

• Commercialization of Early TNF-α Inhibitors: The patent was instrumental in the successful development and launch of blockbuster drugs like infliximab (marketed as Remicade by Janssen Biotech, Inc. and others) and adalimumab (marketed as Humira by AbbVie Inc.). These drugs revolutionized the treatment of chronic inflammatory diseases.
• Incentive for Further Research: The commercial success enabled by this patent provided substantial revenue, which fueled further investment in research and development of other biologic therapies, including those targeting different inflammatory pathways.
• Establishment of Therapeutic Standards: The efficacy and safety demonstrated by drugs derived from this patent established new therapeutic standards for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis, shifting treatment paradigms from symptomatic relief to disease modification.
• Foundation for Biosimilar Development: While the patent’s exclusivity period has expired, it laid the groundwork for the subsequent development of biosimilar versions. The understanding and manufacturing techniques established by the original patent holder informed the scientific and technical approaches used by biosimilar developers.
• Impact on Intellectual Property Strategy: The success of patents like 5,969,156 has informed intellectual property strategies for other biologic drugs, emphasizing the importance of broad claims covering not just the molecule but also its methods of use and manufacturing.

The patent's claims provided a shield for innovation, allowing companies to recoup significant R&D investments. The expiration of the patent, however, has opened the door for increased competition from biosimilars, leading to lower drug prices and broader patient access.

What are the Key Takeaways for R&D and Investment?

The analysis of United States Drug Patent 5,969,156 reveals several critical insights for R&D and investment professionals in the pharmaceutical and biotechnology sectors.

The patent represents a foundational intellectual property asset for a class of highly successful TNF-α inhibitors. Its broad claims, covering humanized antibodies, antibody fragments, hybridomas, and therapeutic uses targeting TNF-α, enabled the commercialization of groundbreaking treatments for inflammatory and autoimmune diseases. The patent’s influence extends beyond its direct products, having stimulated further research, established new therapeutic standards, and informed the development of biosimilars.

For R&D professionals, understanding the scope and historical context of such foundational patents is crucial for navigating the innovation landscape. It highlights the importance of identifying unmet medical needs and developing novel therapeutic modalities with robust intellectual property protection. For investors, the patent's lifecycle—from its grant through exclusivity and eventual expiration leading to biosimilar competition—provides a case study for assessing the long-term value of biologic drug patents, market dynamics, and the strategic implications of patent expiry. The ongoing patenting activity in related areas, such as novel antibody formats and combination therapies, underscores the continued potential for innovation and investment within the broader TNF-α inhibitor space.

Frequently Asked Questions

1. What is the expiration date of Patent 5,969,156?

Patent 5,969,156 expired on October 12, 2016.

2. What specific diseases are covered by the therapeutic use claims in Patent 5,969,156?

The patent claims methods of treating diseases mediated by TNF-α. While specific diseases are not exhaustively listed within the claims themselves, the patent's context and prosecution history indicate a primary focus on inflammatory and autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis, where TNF-α plays a significant pathogenic role.

3. Can biosimilar versions of drugs derived from Patent 5,969,156 be developed and marketed?

Yes, biosimilar versions of drugs that were protected by Patent 5,969,156 can be developed and marketed once the patent's exclusivity period has ended. The development of biosimilars involves demonstrating a high degree of similarity to the reference biologic product in terms of quality, safety, and efficacy.

4. Did Patent 5,969,156 protect the manufacturing process itself, or just the resulting molecule and its use?

Patent 5,969,156 includes claims related to the production of the binding proteins and hybridomas producing the antibodies. Therefore, it protected certain aspects of the manufacturing process, specifically those involving the creation of the humanized antibodies and the cell lines that produce them, in addition to the molecules and their therapeutic uses.

5. What is the relationship between Patent 5,969,156 and the specific drug product infliximab?

Patent 5,969,156 is a foundational patent that describes the humanized antibody technology, including the antibody derived from the murine antibody A2. Infliximab (Remicade) is a specific chimeric monoclonal antibody that targets TNF-α. While infliximab's development preceded some aspects of the humanization described in 5,969,156, the patent family and related intellectual property provided critical protection for the underlying antibody engineering and therapeutic principles that advanced the field and influenced subsequent TNF-α inhibitor development, including the lineage leading to therapies like infliximab.

Citations

[1] Celltech R&D Limited. (1999). United States Patent 5,969,156: Antigen binding proteins and peptides and their use in preventing and treating disease. U.S. Patent and Trademark Office.